Cynthia Reilly directs Pew's work on federal and state initiatives to reduce the inappropriate use of prescription opioids while ensuring that patients have access to effective pain management. She also focuses on expanding access to effective treatment for substance use disorders through increased use of medication-assisted treatment.
Prior to joining Pew, Reilly worked on issues related to the safety and quality of medication use for the American Society of Health-System Pharmacists in Bethesda, Maryland. Areas of focus included the development of clinical policy, dissemination of best practices to improve patient outcomes, and coordination of initiatives aimed at ensuring the availability and integrity of drug products. In this role, she coordinated the society’s work in support of rescheduling hydrocodone combination products from Schedule III to Schedule II to improve the safe and appropriate use of those therapies. In addition, she led development of policy that called on clinicians to increase efforts to combat prescription drug abuse while also ensuring patient access to needed pain therapies.
Reilly received her bachelor’s degree in pharmacy from Temple University and her master’s degree in global health and medical policy from George Mason University.
Recent WorkView All
In November, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule intended to protect Medicare beneficiaries who are at risk from opioid misuse. The rule sets expectations for insurers developing drug management programs known as patient review and restriction (PRR) programs, which are used to identify at-risk patients and assign them to designated prescribers and/or... Read More
Despite two recent high-profile events related to the opioid crisis—the Trump administration’s announcement of a public health emergency and the release of the final report from the Commission on Combating Drug Addiction and the Opioid Crisis—more action is needed by the administration and Congress. In particular, funding is necessary to carry out the evidence-based... Read More
Insurance coverage for the treatment of substance use disorders (SUDs)—which include the misuse of opioids, alcohol, and other drugs—varies dramatically among private and public insurers. While some payers cover the full spectrum of services recommended by evidence-based guidelines, others include arbitrary restrictions or omit coverage for services and medications approved for these... Read More